Pesquisar
EyePoint Pharmaceuticals Inc
EYPTAdicionar à lista de desejos
13.980USD
+0.785+5.95%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
1.16BValor de mercado
PerdaP/L TTM
Mais detalhes de EyePoint Pharmaceuticals Inc Empresa
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Informações de EyePoint Pharmaceuticals Inc
Código da empresaEYPT
Nome da EmpresaEyePoint Pharmaceuticals Inc
Data de listagemJan 27, 2005
CEODuker (Jay S)
Número de funcionários165
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 27
Endereço480 Pleasant Street, Suite C400
CidadeWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Telefone16179265000
Sitehttps://eyepointpharma.com/
Código da empresaEYPT
Data de listagemJan 27, 2005
CEODuker (Jay S)
Executivos da empresa EyePoint Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Perguntas frequentes
Quem são os cinco principais acionistas de EyePoint Pharmaceuticals Inc?
Os cinco principais acionistas de EyePoint Pharmaceuticals Inc são: Dr. Jay S. Duker, M.D.
Quantas instituições possuem ações da EyePoint Pharmaceuticals Inc (EYPT)?
Em 2026Q1, 381 instituições possuíam ações da EyePoint Pharmaceuticals Inc, com valor de mercado aproximado de 88.53M, representando 105.59% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2754490.00.
Qual é a maior fonte de receita da EyePoint Pharmaceuticals Inc?
Em 2026Q1, o segmento de negócios YUTIQ gerou a maior receita para EyePoint Pharmaceuticals Inc, totalizando 1.60M e representando 5.10% da receita total.